
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
April 10, 2018

MRI INTERVENTIONS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

5 Musick
Irvine, Ca. 92618
(Address of principal executive offices, zip code)

(949) 900-6833
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure

On April 10, 2018, MRI Interventions, Inc. posted an updated investor presentation to its website at <http://ir.stockpr.com/mriinterventions/investor-presentation>. A copy of the investor presentation is being furnished herewith as Exhibit 99.1. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The information contained in Exhibit 99.1 is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make from time to time, by press release or otherwise. The Company undertakes no duty or obligation to publicly update or revise the information contained in this investor presentation, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing or other reports or documents with the SEC, through press releases or other public disclosure.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

[Exhibit 99.1](#) [Investor Presentation dated April 2018.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 10, 2018

MRI INTERVENTIONS, INC.

By: /s/ Harold A. Hurwitz

Harold A. Hurwitz

Chief Financial Officer



Investor Presentation

Joe Burnett, President & CEO


April 2018



Forward Looking Statements


Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's ability to obtain additional financing; estimates regarding the sufficiency of the Company's cash resources; future revenues from sales of the Company's ClearPoint® System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint System products. More detailed information on these and additional factors that could affect the Company's actual results are described in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2017, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which the Company intends to file with the Securities and Exchange Commission on or before May 15, 2018.





Leading the Movement to *Minimally Invasive* *Neurosurgery*

Traditional Stereotactic Neurosurgery is Limited



3 Primary Challenges:



1. The Skull is not 'See Through'
2. X-Ray does not show structures of the brain, and Large, Metallic Frames are not compatible inside an MRI Magnet
3. Precision is lost for each 'estimate' made to keep the procedure in the OR

Additionally the older reference MRI cannot show 'brain shift' which can occur the skull is opened for the first time

The Solution: ClearPoint® Neuro Navigation System Platform



The only Neuro-Navigation System with 'Sub-millimeter' Accuracy

ClearPoint Procedure Overview:



ClearPoint Video
Entry and Trajectory

ClearPoint Video
Alignment and Insertion



Our Unique Value: We DECIDE, GUIDE & CONFIRM the most challenging neurosurgery therapies

Decide

1

Advanced Planning Software and Fusion Algorithms enable 'Fly Through' entry point and trajectory planning the day of the procedure using live MRI Images

Guide

2

Uniquely enable changes to trajectory live, in the MRI, to accommodate anatomical shift or procedural challenges to deliver pinpoint or *CLEARPOINT accuracy*

Confirm

3

Take final images and measurements of the targeting cannula in place to confirm the patient had the best possible chance at success before ending the therapy procedure

Our PLATFORM enables CHOICE of Precision-Guided Therapies for DBS, LITT, Biopsy and Drug Delivery






MRIC: The Premier Company for Precision MRI-Guided Therapy

- **MRI Interventions: Leader in Precision MRI-Guided Therapy**
 - Unique Platform that allows delivery of therapies to the brain with pinpoint accuracy under live MRI Guidance
 - Entire procedure can take place in the MRI suite, reducing the risk of hospital acquired infections and complications
 - Extensive Intellectual Property position: 70+ issued US patents, 45 international
- **Procedure Growth Fueled By Expanding Installed Base and Increased Utilization**
 - 52 Installed systems in the U.S. at leading Neurosurgery Hospitals and Teaching Programs
 - Each new system placement enables razor – razorblade disposable product sales
 - Procedure count continues to grow; 43% CAGR (est.) the past four years
 - Established direct sales channel totaling 16 people supporting cases in the U.S.
- **Expanding Platform into Adjacent Areas to Address Additional Unmet Medical Needs**
 - Five current Biologics and Drug Partners using ClearPoint as Delivery system for therapy trials
 - Internally developed Neuro-Aspiration device will add therapy to our sales team portfolio
 - Existing and New addressable markets > \$1B in potential




Precision MRI-Guided Platform: ClearPoint Neuro Navigation System

ClearPoint Components:

Capital Sale		Recurring Revenue
Reusable Hardware Components	Integrated Software	Single-Use, Disposable Components
		
\$100K - \$175K ASP		~\$7,500 ASP Procedure



Emory University Hospital



Univ. of California San Francisco
Medical Center



Univ. of Pittsburgh
Medical Center



Broad and Growing User Base of Leading Neurosurgeons

ClearPoint Is Installed in 52 Top US Hospitals and Growing

*UC San Francisco
San Francisco VA
Stanford Univ
UCSF Benioff Childrens
USC
UC San Diego
Univ of Colo
Univ of Utah
Univ of Arizona
Cook Children's
MD Anderson
Methodist Hosp
Texas Children's Hosp
Riverside
Nationwide Children's
Children's Mercy
Kansas Univ Med Center
Univ of Wisconsin
Spectrum Health
Ohio State Univ
Univ of Cincinnati
Univ of Michigan*



*Univ of Minnesota Med Ctr
Brigham & Women's
Boston Children's
Yale Univ
Univ of Pitt Med Center
Memorial Sloan Kettering
Hackensack Univ Med Center
Cornell
Central Du Page
Nat. Institutes of Health
Nat Children's Hospital
Children's Hosp of Philadelphia
Univ of Virginia
Emory University
Carillion
Duke University
Children's of Alabama
CHOA Scottish Rite
Willis Knighton
Mayo Clinic Jacksonville
Miami Children's*

Strong Commercial Sales and Clinical Support Teams in Place



Our MRI-Guided Therapy Platform is Currently Being Used to:

Implant Neuro Stimulation Leads from:

- Medtronic
- St. Jude Medical
- Boston Scientific
- NeuroPace



Place Laser Ablation Probes from:

- Medtronic-Visualase
- Monteris Medical



Deliver Biologics and Drugs from:

- Voyager
- Medicenna
- Oxford Biomedica
- International Stem Cell Corporation




MRIC Platform Runs on All Major Scanners:


- Siemens
- GE
- Philips
- IMRIS



ClearPoint Neurosurgical Procedure Growth




Consistent Revenue Growth Since 2013



> 80% of 2017 revenue from single-use disposable kits and cannulas



MRIC: 4-Part Growth Strategy



Target Indications of > 150,000 procedures per year represents
Potential Addressable Market for MRIC of \$1B+


Note: Market sizes for brain tumor, ICH are Pancreatic cancer are incidence numbers because of the nature of those diseases. Prevalence numbers are based on either market research conducted by a third party on behalf of MRI Interventions or research conducted by MRI Interventions of publicly available sources.




Part ①: Grow Our Core Functional Neurosurgery Business

Focus on Complex Procedures Where Precision is Paramount

**Electrode Placement for
Deep Brain Stimulation**



**Laser Catheter Placement
for Ablation Procedures**



Key Strategies & Tactics for 2018:


- Add 8-10 new centers from existing funnel via capital sales and evaluation agreements
- Publish 'Best Practices' workflows to get procedures predictably under four hours enabling two procedures a day in MRI scanners instead of one, present to entire installed base
- Launch ClearPoint 2.0 Fusion software in 2H 2018 to reduce trajectory planning time
- Pursue clinical pathway for an 'Asleep DBS' Indication to allow more substantial marketing, training and education of the benefits of asleep procedures which patients desire
- Build more substantial strategic partnerships for system integration, co-marketing and training



Part ①: Grow Our Core Functional Neurosurgery Business

Focus on Complex Procedures Where Precision is Paramount


ClearPoint 2.0 Image Fusion Feature
(Not Commercially Available)




Part ②: Become the Premier Partner for Biologics and Drug Delivery

Focused Resources for Branding, Device Development and Distribution

Precise, Quantifiable
Drug Delivery



ClearPoint 2.0 Software
(not commercially available)




Key Strategies & Tactics for 2018:

- Assign a 'Sales Portfolio Manager' to proactively build our brand as the premier partner in biologics and drug delivery to the brain
- Launch ClearPoint® 2.0 software with live volumetric measurement capability
- Begin VOYAGER phase II trial enrollment
- Add 1-2 additional partnerships for Phase 1 Trials

Part ②: Become the Premier Partner for Biologics and Drug Delivery


Focused Resources for Branding, Device Development and Distribution



Part ②: Become the Premier Partner for Biologics and Drug Delivery


Focused Resources for Branding, Device Development and Distribution

Dose-Dependent Increases in AADC Activity and Corresponding Decreases in Oral PD Medications at 6 months



Part 3: Expand into Direct Therapy Markets

Achieve first-in-human case for our Neuro-Aspiration System



Integrated Therapy Products benefit the patient and hospital by simplifying workflow and making procedures more efficient and cost effective

Adding therapy helps MRIC generate additional revenue per procedure



Part 3: Expand into Direct Therapy Markets

Achieve first-in-human case for our Neuro-Aspiration System

Initial Stroke Product (ClearAway™) Targets Intracerebral Hemorrhage (ICH)

- Collaboration with Mayo Clinic
- Only major stroke subtype w/o clearly effective therapy – major unmet medical need
- Affects 80,000 to 100,000 people in the US each year


Current Approaches for Hemorrhage Removal and Decompression are Inadequate:

- Open craniotomy provides visibility but is highly invasive, destroys brain tissue
- Minimally invasive approach has very limited ability to quantify volume reduction of the hemorrhage or monitor subsequent bleeds

Our Unique ClearAway™ Approach to ICH

- Detailed, continuous, high resolution, 4-D visibility
- Minimally invasive approach
- 95% of current sites already have a stroke program

4-D Guidance of Neuro Clot Aspiration




Key Strategies & Tactics for 2018:

- Complete product development for FDA submission in Q3
- Perform first-in-human case by December 2018



Part 4: Achieve Business Model Scale, Go Global

Execute initiatives along a path-to-profitability



- Relocating Clinical Specialists closer to case 'clusters' to reduce travel
- Hiring new specialists to locations where new placements are planned
- Prioritize shorter procedure times so two cases are performed in the same day

Part 4: Achieve Business Model Scale, Go Global

Execute initiatives along a path-to-profitability

Manufacturing Facility in Irvine, CA




- Current facility capable of producing 5x more product without expansion
- Target gross margin expansion above 70% in next five years

SmartFlow® Drug Delivery Cannula



- Global Strategy being prioritized based on adoption of partner therapies
- Inclusion of ClearPoint® and SmartFlow® Cannulas in more OUS drug trials will be additional driver










Cash Flow From Operations*: 2015 – 2017



*Excludes interest payments, non-cash compensation and financing costs © 2018 MRI INTERVENTIONS, INC. | 23

Experienced Medical Device Management Team

Management Team

Joseph Burnett	CEO	  
Peter Piferi	COO	  
Wendelin Maners	VP Marketing	 
Hal Hurwitz	CFO	 

Board of Directors

<p>Joseph Burnett</p>   	<p>Kimble Jenkins, Chairman</p>  	<p>John Fletcher</p>  <i>Managing Partner, Founder</i>	<p>Pascal Girin</p>  	<p>Timothy Richards</p>   	<p>Maria Sainz</p>    	<p>Jack Spencer</p> 
--	--	--	--	--	---	--



MRIC: Executive Summary

- Unique, Platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders
- Large, Growing installed base in 52 of 250+ leading Neurology centers in U.S.
- Procedure volume has grown 43%+ CAGR from 2013-2017
- 80%+ of current revenue from single-use, high-margin disposables
- Pipeline of new revenue streams from product improvements, new drug therapy trials, and standalone therapy products
- Total potential addressable market > \$1B for our products and pipeline
- Strong cash position to fund Commercial and R&D initiatives
- A passionate team of embedded scientists and specialists

